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This multicentre, randomised, double-blind, placebo-controlled, parallel-group study investigated the efficacy, safety and phar-
macokinetics of remacemide hydrochloride in adult patients (n = 59) with refractory epilepsy, undergoing reduced or dis-
continued antiepileptic drug (AED) usage, as part of an evaluation for epilepsy surgery. On discontinuation or reduction of
maintenance AEDs, patients received remacemide hydrochloride, up to 600 mg daily, or placebo, for up to ten days or until
they experienced a fourth complex partial (CPS) or a generalised tonic–clonic (GTC) seizure. Pre- and post-study blood and
urine samples were taken for analysis. Remacemide hydrochloride showed a significantly (P = 0.045) longer median time to
fourth seizure compared with placebo (6.8 vs. 3.8 days). Median nine-day seizure counts were significantly (P = 0.0327) lower
with remacemide hydrochloride than placebo (6.2 vs. 12.8). Eleven remacemide hydrochloride patients and six placebo patients
completed ten days’ treatment. Remacemide and desglycinyl metabolite levels were lower in patients receiving concomitant
carbamazepine or phenytoin than in those receiving non-inducing AEDs or remacemide hydrochloride alone. No serious adverse
events occurred; all patients receiving remacemide hydrochloride completed the study. Remacemide hydrochloride was well
tolerated and showed significant therapeutic activity in this patient population.
c© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
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INTRODUCTION
Remacemide hydrochloride is a novel anticonvulsant
which is being developed for the treatment of
epilepsy. The drug and its principal active desg-
lycinyl metabolite are low-affinity, non-competitive
N-methyl-D-aspartate (NMDA) antagonists1, 2. Both
compounds are also potent sodium fast channel block-
ers. Remacemide hydrochloride is effective in a range
of animal models suggesting broad anticonvulsant
activity1.
Clinical studies with remacemide hydrochloride
as adjunctive therapy, conducted in patients with
medically refractory epilepsy, have shown a good
safety and tolerability profile at doses of up to 1200 mg
per day. Statistically significant differences in 50%
responder rates compared to placebo have been shown
at doses between 800 mg and 1200 mg per day3, 4.
The purpose of this study was to assess the safety and
efficacy of remacemide hydrochloride in the treatment
of medically refractory epilepsy in patients who had
concomitant AED therapy reduced or withdrawn as
part of an evaluation for surgery. The pharmacokinetic
profiles of remacemide and the desglycinyl metabolite
were also evaluated in these patients.
PATIENTS AND METHODS
Patients
All patients were subject to complex partial seizures
(CPSs) with or without secondary generalisation, as
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defined in the International Classification of Seizures5
and had experienced at least four but not more than
16 CPSs during the last four days of the surgical
evaluation period. Patients who had also experienced
up to three generalised tonic–clonic (GTC) seizures
during the same time period were eligible for
admission. Interictal duration had to be greater than
two hours.
Prior to entering the study, the patients’ medical
histories including seizure and AED history and
AED withdrawal were recorded. The presence of
localisation-related epilepsy was confirmed by EEG
and the absence of a treatable lesion confirmed
by computed tomography or magnetic resonance
imaging. Patients were required to have undergone
an ECG and a chest X-ray, within the previous year
without significant findings.
Patients with significant psychiatric disorder or
recurrent depression, progressive neurological disor-
ders, a history of recurring status epilepticus while on
adequate AED therapy, nonepileptic seizures within
five years or any other serious medical disorder were
excluded from the study. Also excluded were female
patients at risk of pregnancy.
Written informed consent was obtained from each
patient prior to the initiation of any study-related pro-
cedures, and the study was conducted in accordance
with the principles of the Declaration of Helsinki
and with the approval of the appropriate Institutional
Review Board.
Study design
This was a randomised, double-blind, placebo-
controlled, parallel-group study carried out at six
centres in the USA. On completion of the presurgical
evaluation, eligible patients were randomised to
receive either remacemide hydrochloride or placebo
for a period of up to ten days or until either the
fourth CPS or GTC seizure from the beginning
of day 2. Patients in the active group received
remacemide hydrochloride four times daily. On
day 1 they received a total of 450 mg calculated
as remacemide free base (50 mg at 08.00 h,
100 mg at 12.00 h, 150 mg at 18.00 h and
150 mg at 22.00 h). On subsequent days they
received four doses of 150 mg following the same
dosing schedule, to provide a total daily dose of
600 mg remacemide hydrochloride. The control group
received an equivalent number of matching placebo
capsules.
A dose of lorazepam (according to body weight) was
given at the start of day 1 to patients who experienced
at least three CPSs or one GTC seizure within the 24 h
immediately prior to randomisation. These patients
received a further dose of lorazepam 12 h after the
first dose. Lorazepam was then discontinued for the
duration of the study.
Prior to receiving study treatment patients were
given a physical examination, vital signs were
recorded, blood and urine samples were taken for
haematology, biochemistry, urinalysis, and where
appropriate a pregnancy test was carried out. Neuro-
logical examinations were carried out daily throughout
the treatment period. Baseline blood samples for
analysis of remacemide and the desglycinyl metabolite
were taken prior to the first dose on day 1.
Further blood samples were taken at trough and
during the first dosing interval at 15, 30, 45, 60 and
90 min and two, three, four and six hours after dosing
on days 3 and 7. Plasma samples were analysed using
solid phase extraction followed by high performance
liquid chromatography (HPLC) with ultraviolet (UV)
detection at 210 nm. The limit of quantification for
both remacemide and the desglycinyl metabolite in
plasma was 10 ng/ml. On days 3 and 7, maximum
plasma concentration (Cmax), time to reach Cmax
(tmax) and the area under the plasma concentration
curve over the dosing interval (AUC0−6 h) were
derived.
Statistical methods
All patients who remained in the study for at least
24 h from the point of randomisation and first dose
of drug, were included in the analysis (the evaluable
population). A patient completed the study upon
having had four seizures between the beginning of
day 2 and day 10, or upon reaching day 10 without
experiencing a fourth seizure. The primary efficacy
endpoint was the time to fourth seizure during ten days
of therapy. All seizures were recorded but only CPS
and GTC seizures which occurred in days 2 through
10 were counted toward meeting the 4-seizure exit
criterion. Time-to-exit was analysed using the Gehan’s
generalised Wilcoxon statistic.
A further analysis was conducted on the evaluable
population in which an extrapolated value of the
number of seizures in nine days was estimated from
the time-to-exit variable. For all the patients that
completed the study, this value was derived from the
ratio of seizure counts to time on study (from the
beginning of day 2 until completing the study):
Nine-day value = 9× No. of seizures starting from day 2 until completion
No. of days in trial starting from day 2
.
The equation assigned a standard nine-day interval
to each patient. The number of seizures placebo-
treated patients had, before leaving the study, was
imputed for their seizure count in nine days; this
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provided the most conservative approach. This
analysis ranked each patient dependent on the number
of seizures experienced by that patient in nine days.
The Wilcoxon rank sum test was applied to these
ranks to test for treatment group differences. Similar
analyses were also carried out on patients who
completed the study.
Table 1: Patient demographic data.
Treatment group
Remacemide
hydrochloride Placebo Total
Sex Male 23 16 39
Female 6 16 22
Age (Years) Mean 34.1 34.2 34.2
Range 20–55 18–59 18–59
Lorazepam 17 19 36
taken
Table 2: Summary of exit times for remacemide hydrochloride
and placebo monotherapy patients fulfilling exit criteria.
Within-group range, Time to exit (days)
Treatment group Minimum Maximum Median
Placebo 1.44 4.7 3.7
Remacemide 2.26 10.0 6.8
RESULTS
Sixty-one patients entered the study, 29 in the
remacemide hydrochloride group and 32 in the
placebo group. Four patients, all from the placebo
group, failed to complete the study. One patient was
withdrawn after six hours due to experiencing two
GTCs which required parenteral intervention and one
patient requested withdrawal after 17 h without stating
a reason. These two patients were not included in the
efficacy analysis as they did not complete the specified
24 h period following the first treatment. The other two
patients remained in the study for sufficient time to
be included in the evaluable population analysis. The
investigator withdrew one of these patients after 28 h
due to concern over a pre-study cardiac event and the
other withdrew after three days due to anxiety about
hospitalisation. These two patients were excluded
from the completer population. Patient demographics
are summarised in Table 1. No significant differences
were seen between the two treatment groups except
for a significantly greater percentage of males in the
remacemide hydrochloride group.
Clinical efficacy
Of the 59 patients included in the analysis, six
placebo patients and nine remacemide hydrochloride
patients had their concomitant AEDs completely with-
drawn and received either remacemide hydrochloride
monotherapy or placebo only. Of these, all but one
patient (on placebo) reached the exit criterion of
experiencing four seizures or completing ten days of
treatment (Table 2). The remaining patients continued
to receive one or more concomitant AEDs (Table 3).
Table 3: Numbers of patients taking concomitant AEDs
during the study.
Treatment group
Remacemide
Concomitant AED hydrochloride Placebo Total
Carbamazepine 12 16 29
Felbamate 2 4 6
Gabapentin 2 2 4
Phenytoin 2 0 2
Valproate 2 2 4
None 9 6 15
Compared with placebo, the remacemide
hydrochloride group showed a statistically
significantly longer median time to fourth seizure,
in both the evaluable patient population (P = 0.045),
and the study-completing population (P = 0.016)
(Table 4). Furthermore, the extrapolated number of
seizures in nine days in the remacemide hydrochloride
group was statistically significantly lower than in the
placebo group, in both the evaluable patient population
(P = 0.033) and the study-completing population
(P = 0.010) (Table 4).
Five non enzyme-induced patients (four of whom
were receiving remacemide hydrochloride mono-
therapy) and six enzyme-induced patients completed
the study without experiencing a fourth seizure, sug-
gesting a comparable efficacy profile for remacemide
hydrochloride in the presence or absence of hepatic
enzyme induction. Eleven evaluable patients on
remacemide hydrochloride and six patients on placebo
completed ten days’ treatment.
Pharmacokinetics
The mean pharmacokinetic parameters are sum-
marised in Table 5. The data indicate that plasma
concentrations of remacemide and the desglycinyl
metabolite were lower in patients who were assumed
to be hepatically enzyme-induced due to taking
concomitant carbamazepine or phenytoin than in
those receiving non-inducing AEDs or remacemide
hydrochloride alone. The mean AUC(0−6 h) values
for remacemide and the desglycinyl metabolite were
considerably smaller at steady-state concentrations for
induced patients than for non-induced patients at both
day 3 and day 7.
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Table 4: Analysis of time to fourth seizure and extrapolated value for number of seizures during days 2 to 9.
Population Time to exit (days)a Wilcoxon-Gehan
(P value)
Extrapolated number of
seizures per 9 days
Wilcoxon rank
sum (P value)
Remacemide
hydrochloride
Placebo Remacemide
hydrochloride
Placebo
Evaluable
N 29 30 29 30
median 6.8 3.8 6.21 12.80
mean 5.74 4.31 0.045 12.19 30.77 0.033
Completed
N 29 28 29 28
median 6.8 3.7 6.21 13.21
mean 5.74 4.08 0.016 12.19 32.89 0.01
a Patients exited the study after experiencing a fourth seizure or on completing day 10 without experiencing a fourth seizure.
Table 5: Mean pharmacokinetic parameters recorded on days 3 and 7.
Remacemide day 3 Remacemide day 7
Mean (±SD) Mean (±SD)
Induced Non-induced Induced Non-induced
AUCt (ng/h/ml) 749.6 (225.4) 1262.7 (447.1) 753.6 (201.3) 1288.0 (429.9)
Cmax (ng/h/ml) 282.9 (151.8) 596.1 (267.2) 349.5 (347.4) 458.1 (250.7)
tmax (h) 2.04 (1.51) 1.04 (0.81) 1.95 (1.15) 1.58 (1.05)
AR-R12495 day 3 AR-R12495 day 7
Mean (±SD) Mean (±SD)
Induced Non-induced Induced Non-induced
AUCt (ng/h/ml) 84.6 (15.9) 429.5 (241.7) 104.7 (22.2) 439.5 (226.1)
Cmax (ng/h/ml) 15.2 (4.6) 107.3 (77.2) 25.3 (8.3) 86.8 (43.1)
tmax (h) 2.4 (1.81) 1.86 (1.03) 2.41 (3.11) 2.08 (1.75)
Adverse events
There were no serious or unexpected adverse
events (AEs) and the overall incidence of AEs
was similar in the remacemide hydrochloride and
placebo groups (138 and 130 respectively). The most
commonly reported events (>5% of patients across
both treatment groups) were headache, somnolence,
nausea, accident or injury, dyspepsia, dizziness,
nervousness, tremor, vomiting, and ataxia (Table 6).
Dyspepsia was the only AE which showed a statisti-
cally significant difference between treatment groups.
Six remacemide hydrochloride patients reported this
event compared to one placebo patient (P = 0.022).
No patients withdrew from the study due to any AE
which might have been attributable to remacemide
hydrochloride.
Mean baseline and exit values for all laboratory
parameters were within normal ranges with the
exception of gamma glutamyl transpeptidase (GGT)
for which the mean value was 101.86 units per
litre (U/L) for the placebo group and 83.07 U/L for
the remacemide hydrochloride group, representing a
mean baseline approximately 1.28 times the normal
upper limit. While mean values for both groups rose
slightly, to 113.3 U/L for placebo and 85.65 U/L
for remacemide hydrochloride, more shifts were
observed in the placebo patients. High baseline
values for GGT are often observed in patients
receiving enzyme-inducing AEDs. Some variations
were seen in laboratory parameters in remacemide
hydrochloride and placebo patients but were generally
of a low magnitude and clinically unimportant. Five
remacemide hydrochloride and three placebo patients
experienced increases in alanine aminotransferase
(ALT/SGPT). Decreases in red blood cell count (RBC)
were seen in five remacemide hydrochloride patients
accompanied by increases in lymphocyte count in
three patients and a decrease in white cell count in one
patient. None of the changes in laboratory parameters
were considered clinically significant. No clinically
significant changes were seen in vital signs.
DISCUSSION
Fifteen patients, nine in the remacemide hydrochloride
group and six in the placebo group achieved total
withdrawal from existing AED therapy prior to
entering the study. The median time to exit was
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Table 6: The most commonly reported AEs (>5% of patients across both treatment groups).
Placebo (n = 32) Remacemide (n = 29) Total (n = 61)
WHOART Preferred
Term
Number of
patients with
AE
% Number of
patients with
AE
% Number of
patients with
AE
%
Headache 9 28.1 5 17.2 14 23.0
Somnolence 4 12.5 8 27.6 12 19.7
Nausea 5 15.6 5 17.2 10 16.4
Accident and/or injury 5 15.6 3 10.3 8 13.1
Dyspepsia 1 3.1 6 20.7 7 11.5
Dizziness 5 15.6 3 10.3 8 13.1
Nervousness 4 12.5 3 10.3 7 11.5
Tremor 3 9.4 4 13.8 7 11.5
Vomiting 3 9.4 4 13.8 7 11.5
Ataxia 3 9.4 2 6.9 5 8.2
6.8 days for patients receiving remacemide hydrochlo-
ride monotherapy and 3.7 days for patients receiving
placebo monotherapy.
Analyses of data from all patients who completed at
least 24 h in the study, and a separate analysis of those
patients who reached the exit-point, showed statisti-
cally significant differences in favour of remacemide
hydrochloride compared with placebo, both in the
length of time to the fourth seizure, and in the
extrapolated value for the number of seizures during
days 2 to 10. These data support previous add-on
studies which have shown remacemide hydrochloride
to have therapeutic activity in patients with refractory
epilepsy3, 4. Altogether, remacemide hydrochloride
showed a two-fold improvement over placebo at a
dose of 600 mg/day, a relatively low dose for enzyme-
induced patients.
There were no serious AEs, and no patients in the
remacemide hydrochloride group withdrew from the
study. Variations were seen in some laboratory param-
eters in both remacemide hydrochloride and placebo
patients. These were generally low in magnitude and
were considered to be of no clinical importance.
Remacemide hydrochloride was well tolerated by
the patients in this study. The qualitative and quanti-
tative incidence of AEs was similar in the remacemide
hydrochloride and placebo patient groups. Overall,
our results indicate that remacemide hydrochloride
has therapeutic activity in patients with medically
refractive epilepsy at a dose of 600 mg/day. A sub-
group of patients in which concomitant antiepileptic
drugs were withdrawn completely, demonstrated a
similar response, indicating the potential activity of
remacemide hydrochloride as monotherapy.
There is an ethical dilemma concerning placebo-
controlled monotherapy trials of new AEDs. It is
generally unacceptable to withhold effective treatment
from a patient with epilepsy. As a result, in the
majority of studies, the drug under investigation is
added to the drug already being taken as maintenance
therapy. There may, however, be pharmacokinetic
or pharmacodynamic interactions between the new
drug and other drugs that prevent any confident
interpretation of data from such studies as showing
efficacy of the new drug as monotherapy. In an attempt
to overcome these difficulties various approaches have
been made to develop trial designs in which it might
be ethically possible to subject individuals to no
treatment or to sub-optimal treatment6.
The presurgical AED trial design was conceived
to overcome the limitations of placebo-controlled
monotherapy trials, while ensuring a high degree
of patient safety7. At the time this study was
conducted, all the authors believed that this design
was important for proof of concept and initial
monotherapy exploration, and contained effective
patient safety provisions. However, even this design
has some shortcomings, and the issue of monotherapy
study methods continues to be debated8, 9. These
criticisms do not undermine the scientific validity
of the conclusion that remacemide was effective
as monotherapy in this trial. At the present time,
the optimal monotherapy trial design that satisfies
both regulatory requirements and provides ethically
acceptable ‘best treatment’ for patients remains a topic
of discussion.
ACKNOWLEDGEMENTS
This study was sponsored by the National Institute of
Neurological Disorders and Stroke, National Institutes
of Health (NINDS, NIH). The authors would like
to thank Dr Stephen Clegg, the Medical Writer who
assisted in the preparation of this manuscript.
376 O. Devinsky et al.
REFERENCES
1. Muir, K. T. and Palmer, G. C. Remacemide. In: New
Antiepileptic Drugs Epilepsy Res. Suppl. 3, (Eds F. Pisani,
G. Perucca, G. Avanzini and E. Richens). Elsevier Science
Publishers B.V. (Biomedical Division), 1991: pp. 147–152.
2. Palmer, G. C., Murray, R. J., Wilson, T. C. et al. Biological
profile of the metabolites and potential metabolites of the
anticonvulsant remacemide. Epilepsy Res. 1992; 12: 9–20.
3. Bialer, M., Johannessen, S. I., Kupferberg, H. J. et al. Progress
report on new antiepileptic drugs: a summary of the Third Eilat
Conference. Epilepsy Res. 1996; 25: 299–319.
4. Jones, M. W., Blume, W. T., Guberman, A. et al. Remacemide
hydrochloride efficacy and safety versus placebo in patients
with refractory epilepsy. Epilepsia 1996; 37 (Suppl. 5): 166.
5. International League Against Epilepsy, International classifi-
cation of epileptic seizures. Epilepsia 1981; 22: 489–501.
6. Pledger, G. W. and Kramer, L. D. Clinical trials of investi-
gational antiepileptic drugs: monotherapy designs. Epilepsia
1991; 32: 716–721.
7. Bourgeois, B., Leppik, I., Sackellares, J. C. et al. Felbamate: a
double-blind controlled trial in patients undergoing presurgical
evaluation of partial seizures. Neurology 1993; 43: 693–696.
8. Chadwick, D. and Privitera, M. Placebo-controlled studies in
neurology: where do they stop? Neurology 1999; 52: 682–685.
9. Schachter, S. C., Vazquez, B., Fisher, R. S. et al. Oxcar-
bazepine in a monotherapy trial for partial seizures. Placebo-
controlled studies in neurology: where do they stop? (letter;
comment). Neurology 1999; 53: 2211–2212.
